Form 4: Corcept Director Swisher Exercises Options, Sells Shares

Corcept Therapeutics Director Daniel N. Swisher Jr. exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan.

Summary

• Daniel N. Swisher Jr., a Director of Corcept Therapeutics Inc., engaged in a pre-planned transaction.
• On September 10, 2025, Mr. Swisher exercised stock options to acquire 2,200 shares of common stock at an exercise price of $14.08 per share.
• Concurrently, he sold all 2,200 newly acquired shares of common stock at a price of $72.45 per share.
• This sale was executed under a Rule 10b5-1 trading plan, which was adopted on August 1, 2024.
• Following these transactions, Mr. Swisher directly owns 0 shares of common stock and 3,300 stock options.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a pre-planned exercise of options and sale of shares by a director, which is a common occurrence and not indicative of new company-specific positive or negative news.

Positives

• The transaction demonstrates a director exercising vested options, indicating a realization of value from previous compensation.
• The sale was conducted under a pre-arranged 10b5-1 plan, which suggests the transaction was not based on new, non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, reduces their direct equity stake in the company to zero, which could be perceived negatively by some investors.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Daniel N. Swisher Jr., a Director of Corcept Therapeutics Inc., engaged in the exercise of stock options and subsequent sale of shares, which is a transaction between a related party (director) and the company's securities.

Stakeholder Impact

• Shareholders: The sale by a director could be viewed with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling. It represents a director monetizing compensation.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (exercise of options and sale of shares) by a director. This type of transaction, executed under a 10b5-1 plan, typically does not convey new material information about the company's prospects and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should maintain their current position and consider broader company fundamentals and market conditions.

Keywords

Corcept Therapeutics, CORT, Daniel N. Swisher Jr., Director, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, SEC Form 4, Biotechnology, Pharmaceuticals